The Mechanism of Action of Cancer Therapeutic Vaccines and Their Application Prospects

Mingrui  Li

doi:10.62051/2w95tb51

Authors

Mingrui Li

DOI:

https://doi.org/10.62051/2w95tb51

Keywords:

Therapeutic vaccines; application prospect; mechanism.

Abstract

The complexity of cancer as a global health problem has also led to the development of various novel therapeutics, including prophylactic vaccines. Scientific breakthroughs and technological developments have changed cancer research; since cancer is a complicated disease with many factors, more and better vaccines are required. The research stresses the worldwide influence of cancer and modern therapeutic approaches, such as vaccination. With advances in molecular and cellular biology, cancer therapeutic vaccination studies have been advanced; the discovery of tumor markers and advances in immunology and cancer therapies have changed. In contrast to chemotherapy and radiation, immunotherapy revolutionized treatment. The cancer therapeutic vaccines elicit antigen-specific T cell responses, helper T cell stimulation, and innate immune cells; the research indicates that these vaccines use various means to arouse the body's defensive mechanism against cancer. Complex tools are explained by figures 1 and 2, which depict CD4+ T cells and innate immunity cells. Vaccines can be peptide/protein-based, whole-cell- or nucleic acid-based by application or clinical trial. Each category is looked at for its significant successes, triumphs, and failures: dendritic cell vaccines, the efficiency of antigen presentation, and clinical trial success. Cancer-therapeutic vaccines and immune checkpoint inhibitors are synergistic. Expanding the range of cancer vaccine antigens depends on finding added tumor-associated antigens and immunological checkpoints. However, there are flaws in cancer therapeutic vaccines, despite progress; tumor heterogeneity, immune evasion, and Safety are among concerns today. Recognizing these problems sets the stage for later chapters of optimization and new approaches.

Downloads

Download data is not yet available.

References

Zhang, Z., Liu, S., Zhang, B., Qiao, L., Zhang, Y., & Zhang, Y. T cell dysfunction and exhaustion in cancer. Frontiers in cell and developmental biology, 2020, 8, 17.

Kaczmarek, M., Poznańska, J., Fechner, F., Michalska, N., Paszkowska, S., Napierała, A., & Mackiewicz, A. Cancer vaccine therapeutics: Limitations and effectiveness—A literature review. Cells, 2023, 12 (17), 2159.

Liu, J., Fu, M., Wang, M., Wan, D., Wei, Y., & Wei, X. Cancer vaccines as promising immuno-therapeutics: platforms and current progress. Journal of Hematology & Oncology, 2022, 15 (1), 28.

Tojjari, A., Saeed, A., Singh, M., Cavalcante, L., Sahin, I. H., & Saeed, A. A Comprehensive Review on Cancer Vaccines and Vaccine Strategies in Hepatocellular Carcinoma. Vaccines, 2023, 11 (8), 1357.

Liu, D., Che, X., Wang, X., Ma, C., & Wu, G. Tumor Vaccines: Unleashing the Power of the Immune System to Fight Cancer. Pharmaceuticals, 2023, 16 (10), 1384.

Chandran, S. S., & Klebanoff, C. A. T cell receptor‐based cancer immunotherapy: emerging efficacy and pathways of resistance. Immunological Reviews, 2019, 290 (1), 127 - 147.

Demaria O, Cornen S, Daëron M, et al. Harnessing innate immunity in cancer therapy. Nature, 2019, 574 (7776): 45 - 56.

Zhang, Y., & Zhang, Z. The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cellular & molecular immunology, 2020, 17 (8), 807 - 821.

Richardson J R, Schöllhorn A, Gouttefangeas C, et al. CD4+ T cells: multitasking cells in the duty of cancer immunotherapy. Cancers, 2021, 13 (4): 596.

Buonaguro, L., & Tagliamonte, M. Selecting target antigens for cancer vaccine development. Vaccines, 2020, 8 (4), 615.

Vandenberk, L., Belmans, J., Van Woensel, M., Riva, M., & Van Gool, S. W. Exploiting the immunogenic potential of cancer cells for improved dendritic cell vaccines. Frontiers in immunology, 2016, 6, 663.

Duong E. Elucidating the functional states of tumor-resident dendritic cells that drive productive anti-tumor immunity. Massachusetts Institute of Technology, 2022.

Sadeghi Najaf Abadi, S. A., Bolhassani, A., & Aghasadeghi, M. R. Tumor cell-based vaccine: An effective strategy for eradication of cancer cells. Immunotherapy, 2022, 14 (8), 639 - 654.

Chehelgerdi, M., & Chehelgerdi, M. The use of RNA-based treatments in the field of cancer immunotherapy. Molecular Cancer, 2023, 22 (1), 106.

Yang, B., Jeang, J., Yang, A., Wu, T. C., & Hung, C. F. DNA vaccine for cancer immunotherapy. Human vaccines & immunotherapeutic, 2014, 10 (11), 3153 - 3164.

Stallard, J. New mRNA Pancreatic Cancer Vaccine Trial Starts Next Phase. 2023.

Travieso, T., Li, J., Mahesh, S., Mello, J. D. F. R. E., & Blasi, M. The use of viral vectors in vaccine development. npj Vaccines, 2022, 7 (1), 75.

Kaczmarek, M., Poznańska, J., Fechner, F., Michalska, N., Paszkowska, S., Napierała, A., & Mackiewicz, A. Cancer vaccine therapeutics: Limitations and effectiveness—A literature review. Cells, 2023, 12 (17), 2159.

Gupta, I., Hussein, O., Sastry, K. S., Bougarn, S., Gopinath, N., Chin-Smith, E., ... & Maccalli, C. Deciphering the complexities of cancer cell immune evasion: Mechanisms and therapeutic implications. Advances in Cancer Biology-Metastasis, 2023, 100107.

Liao, J. Y., & Zhang, S. Safety and efficacy of personalized cancer vaccines in combination with immune checkpoint inhibitors in cancer treatment. Frontiers in Oncology, 2021 11, 663264.

Buonaguro, L., & Tagliamonte, M. Peptide-based vaccine for cancer therapies. Frontiers in Immunology, 2023, 14.

Fan, T., Zhang, M., Yang, J., Zhu, Z., Cao, W., & Dong, C. Therapeutic cancer vaccines: advancements, challenges, and prospects. Signal Transduction and Targeted Therapy, 2023, 8 (1), 450.

Hu, Z., Ott, P. A., & Wu, C. J. Towards personalized, tumor-specific, therapeutic vaccines for cancer. Nature Reviews Immunology, 2018, 18 (3), 168 - 182.